financetom
Business
financetom
/
Business
/
Verisk Analytics Q1 Results Seen Inline, Fiscal 2026 Guidance Reiteration Likely, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Verisk Analytics Q1 Results Seen Inline, Fiscal 2026 Guidance Reiteration Likely, RBC Says
Mar 30, 2026 8:33 AM

10:56 AM EDT, 03/30/2026 (MT Newswires) -- Verisk Analytics' ( VRSK ) Q1 results are expected to be inline and the company will likely reiterate its fiscal 2026 guidance, RBC Capital Markets said.

The brokerage said in a Friday note that Verisk's defensive business remains "well-positioned" amid macroeconomic uncertainty, while its $1.5 billion accelerated share repurchase agreement should provide downside support.

Verisk's proprietary data and regulated insurance workflows provide resilience against potential generative AI disintermediation risks. RBC said that Verisk's organic growth is expected to moderate to around 4% in Q1, as its Q4 last year benefited from strong catastrophic bond securitization and overages from robust property underwriting activity.

Analysts said that the company's Q1 was affected by a government work stoppage, and pricing tailwinds could moderate in 2026 within the mid-term guidance range of 3.5% to 4.5%. RBC added that weather-related headwinds likely persisted in the quarter.

The firm has an outperform rating on the stock and a $230 price target.

Price: 187.25, Change: +4.50, Percent Change: +2.46

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Verisk Analytics Q1 Results Seen Inline, Fiscal 2026 Guidance Reiteration Likely, RBC Says
Verisk Analytics Q1 Results Seen Inline, Fiscal 2026 Guidance Reiteration Likely, RBC Says
Mar 30, 2026
10:56 AM EDT, 03/30/2026 (MT Newswires) -- Verisk Analytics' ( VRSK ) Q1 results are expected to be inline and the company will likely reiterate its fiscal 2026 guidance, RBC Capital Markets said. The brokerage said in a Friday note that Verisk's defensive business remains well-positioned amid macroeconomic uncertainty, while its $1.5 billion accelerated share repurchase agreement should provide downside...
MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
Mar 30, 2026
MoonLake Immunotherapeutics ( MLTX ) shares are volatile on Monday as the company is reporting long-term results from its VELA-1 and VELA-2 Phase 3 clinical trials of sonelokimab in patients with hidradenitis suppurativa (HS). HS is a chronic, non-contagious inflammatory skin condition, often called acne inversa, that causes painful, recurring lumps or abscesses, primarily in sweat gland areas like the...
Insmed Sees Rising Physician Adoption of Brinsupri, Morgan Stanley Says
Insmed Sees Rising Physician Adoption of Brinsupri, Morgan Stanley Says
Mar 30, 2026
11:24 AM EDT, 03/30/2026 (MT Newswires) -- Insmed ( INSM ) is seeing growing physician adoption of its Brinsupri therapy, with new survey data indicating expanding use and rising confidence in the drug's long-term potential, Morgan Stanley said in a report Monday. Brinsupri is a prescription drug developed by Insmed ( INSM ) to treat non-cystic fibrosis bronchiectasis. A survey...
Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says
Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says
Mar 30, 2026
11:25 AM EDT, 03/30/2026 (MT Newswires) -- Alumis' ( ALMS ) recent phase 3 results for its psoriasis treatment envudeucitinib is very positive for the company, Oppenheimer said in a note emailed Monday. Envudeucitinib had similar efficacy as Johnson & Johnson's ( JNJ ) icotrokinra and Takeda Pharmaceutical's ( TAK ) zasocitinib, while the Alumis ( ALMS ) drug had...
Copyright 2023-2026 - www.financetom.com All Rights Reserved